| Source: |
| Type: |
| Process through which new blood vessels. Angiogenesis, the process of new blood vessel formation from pre-existing vessels, plays a crucial role in cancer progression and metastasis. Tumors require a blood supply to grow beyond a certain size and to spread to other parts of the body. Vascular Endothelial Growth Factor (VEGF): VEGF is one of the most important pro-angiogenic factors. It stimulates endothelial cell proliferation and migration, leading to the formation of new blood vessels. Many tumors overexpress VEGF, which correlates with poor prognosis. Hypoxia-Inducible Factor (HIF): In response to low oxygen levels (hypoxia), tumors can activate HIF, which in turn promotes the expression of VEGF and other angiogenic factors. This mechanism allows tumors to adapt to their microenvironment and sustain growth. |
| 2511- | H2, | Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation |
| - | in-vivo, | GBM, | U87MG |
| 1643- | HCAs, | Mechanisms involved in the anticancer effects of sinapic acid |
| - | Review, | Var, | NA |
| 2885- | HNK, | Honokiol: a novel natural agent for cancer prevention and therapy |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4640- | HT, | The anti-cancer potential of hydroxytyrosol |
| - | Review, | Var, | NA |
| 4642- | HT, | Hydroxytyrosol, a natural molecule from olive oil, suppresses the growth of human hepatocellular carcinoma cells via inactivating AKT and nuclear factor-kappa B pathways |
| - | in-vitro, | HCC, | HepG2 | - | NA, | NA, | Hep3B | - | NA, | NA, | SK-HEP-1 |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 2179- | itraC, | Repurposing itraconazole for the treatment of cancer |
| - | Review, | Var, | NA |
| 5120- | JG, | Juglone can inhibit angiogenesis and metastasis in pancreatic cancer cells by targeting Wnt/β-catenin signaling |
| - | in-vitro, | PC, | NA |
| 2906- | LT, | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2909- | LT, | Revisiting luteolin: An updated review on its anticancer potential |
| - | Review, | Var, | NA |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2914- | LT, | Therapeutic Potential of Luteolin on Cancer |
| - | Review, | Var, | NA |
| 3267- | Lyco, | Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways |
| - | in-vitro, | Nor, | HUVECs |
| 1708- | Lyco, | The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies |
| - | Review, | Var, | NA |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4515- | MAG, | Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight |
| - | Review, | Var, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 972- | MAG, | Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells |
| - | vitro+vivo, | Bladder, | T24/HTB-9 |
| 1779- | MEL, | Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review |
| - | Review, | BC, | NA |
| 2487- | metroC, | Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2490- | metroC, | Durable complete response of hepatocellular carcinoma after metronomic capecitabine |
| - | Case Report, | HCC, | NA |
| 4092- | MF, | Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology |
| - | Review, | Var, | NA |
| 3536- | MF, | Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis |
| - | Review, | Arthritis, | NA | - | Review, | Stroke, | NA |
| 3478- | MF, | One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study |
| - | Trial, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | C2C12 |
| 3477- | MF, | Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis |
| - | Review, | NA, | NA |
| 3467- | MF, | Pulsed Magnetic Field Induces Angiogenesis and Improves Cardiac Function of Surgically Induced Infarcted Myocardium in Sprague-Dawley Rats |
| - | in-vivo, | Nor, | NA |
| 3466- | MF, | The effect of magnetic fields on tumor occurrence and progression: Recent advances |
| - | Review, | Var, | NA |
| 3465- | MF, | Magnetic fields and angiogenesis |
| - | Review, | Var, | NA |
| 3464- | MF, | Progressive Study on the Non-thermal Effects of Magnetic Field Therapy in Oncology |
| - | Review, | Var, | NA |
| 3482- | MF, | Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice |
| - | in-vitro, | NA, | NA |
| 525- | MF, | Pulsed electromagnetic fields regulate metabolic reprogramming and mitochondrial fission in endothelial cells for angiogenesis |
| - | in-vitro, | Nor, | HUVECs |
| 524- | MF, | Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs) |
| - | vitro+vivo, | PC, | MS-1 | - | vitro+vivo, | PC, | HUVECs |
| 499- | MF, | The Effect of Pulsed Electromagnetic Fields on Angiogenesis |
| - | Review, | NA, | NA |
| - | Review, | NA, | NA |
| 3497- | MFrot, | MF, | The Effect of a Rotating Magnetic Field on the Regenerative Potential of Platelets |
| - | Human, | Nor, | NA |
| 1798- | NarG, | Naringenin: A potential flavonoid phytochemical for cancer therapy |
| - | Review, | NA, | NA |
| 1799- | NarG, | Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics |
| - | Review, | NA, | NA |
| 4970- | Nimb, | Insights into Nimbolide molecular crosstalk and its anticancer properties |
| - | Review, | Var, | NA |
| 4971- | Nimb, | Nimbolide, a Neem Limonoid, Is a Promising Candidate for the Anticancer Drug Arsenal |
| - | Review, | Var, | NA |
| 1229- | OA, | Review of the Clinical Effect of Orlistat |
| - | Review, | NA, | NA |
| 4628- | OLE, | Effects of oleuropein on tumor cell growth and bone remodelling: Potential clinical implications for the prevention and treatment of malignant bone diseases |
| - | in-vitro, | Var, | NA |
| 4646- | OLEC, | Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology |
| - | Review, | Var, | NA |
| 2028- | PB, | Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms |
| - | Review, | Var, | NA |
| 1676- | PBG, | Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies |
| - | Review, | Var, | NA |
| 1660- | PBG, | Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents |
| - | Review, | Var, | NA |
| 1663- | PBG, | Propolis and Their Active Constituents for Chronic Diseases |
| - | Review, | Var, | NA |
| 1664- | PBG, | Anticancer Activity of Propolis and Its Compounds |
| - | Review, | Var, | NA |
| 2381- | PBG, | Chinese Poplar Propolis Inhibits MDA-MB-231 Cell Proliferation in an Inflammatory Microenvironment by Targeting Enzymes of the Glycolytic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:447 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid